Trial Profile
A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Eliglustat (Primary)
- Indications Gaucher's disease type I
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 04 Dec 2018 Results analyzing bone mineral density T- and Z-scores and occurrence of bone pain and bone crises in 4 clinical trials (NCT00358150, NCT00891202, NCT00943111, and NCT01074944) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results of long term pooled safety analysis (n=393) of ENGAGE, ENCORE, EDGE and this study presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 31 Jan 2018 According to a Genzyme Corporation media release, data form the study will be presented at the 14thAnnual WORLDSymposium.